Tyra Biosciences (TYRA)
(Real Time Quote from BATS)
$16.14 USD
+0.47 (3.00%)
Updated Apr 29, 2024 10:56 AM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
TYRA 16.14 +0.47(3.00%)
Will TYRA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TYRA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TYRA
Here's What Could Help Tyra Biosciences, Inc. (TYRA) Maintain Its Recent Price Strength
Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet
TYRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing'
Wall Street Analysts Believe Tyra Biosciences, Inc. (TYRA) Could Rally 59.17%: Here's is How to Trade
Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA)
Other News for TYRA
Tyra Bioscience Poised for Growth: Buy Rating Affirmed Amid Promising Clinical Trials and Strategic Drug Development
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vera Therapeutics (VERA), Tyra Bioscience (TYRA) and Tenaya Therapeutics (TNYA)
Tyra Bioscience Gains Pediatric Disease Designation for Achondroplasia Drug Amid FDA Voucher Uncertainty
Analysts Offer Insights on Healthcare Companies: Nyxoah (NYXH), Tyra Bioscience (TYRA) and Crinetics Pharmaceuticals (CRNX)
Wall Street Analysts Are Bullish on Top Healthcare Picks